

www.diversatechnologies.com info@diversatechnologies.com

DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES

Tracking intracellular delivery of small molecules

USER PROTOCOL - #DIV010

ABOUT THE NANOPARTICLES 1
OVERVIEW 1
COMPONENTS 1
STORAGE 1
EQUIPMENT AND MATERIALS REQUIRED BUT NOT SUPPLIED 2
CONSIDERATIONS BEFORE STARTING 2
DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES
PROTOCOL FOR HYDROPHOBIC DRUGS
PROTOCOL FOR HYDROPHILIC DRUGS
PROTOCOL FOR DRUG LOADING OPTIMIZATION7
EXAMPLE OF ALAMAR BLUE ASSAY CYTOTOXICITY PROTOCOL 9
RECOMMENDATIONS OF USE & TECHNICAL NOTES
FREQUENTLY ASKED QUESTIONS
ONLINE RESOURCES



www.diversatechnologies.com info@diversatechnologies.com

ABOUT THE NANOPARTICLES OVERVIEW

DIVERSA DELIVERY NANOPARTICLES is a biocompatible, biodegradable, and cellfriendly technology for enhancing intracellular delivery of hydrophobic or hydrophilic drugs, paving the way towards clinical translation.

DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES is suitable for hydrophilic and hydrophobic small molecules and can be used to efficiently deliver your drug of interest to specific cell lines and animal models. **DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES** prevents loaded drugs from external degradation and rapid clearance. It promotes optimal and targeted biodistribution, high intracellular absorption and low toxicity, boosting their therapeutic effect.

COMPONENTS

- 1x DIV010 vials for reconstitution.
- 1x DIVTECH vials for preparation of DIVERSA-DRUG REAGENT.
- 2x Tips for 1 mL micropipette.

STORAGE

Before formulating, store the vials at -20 °C. Once formulated, the storage is recommended at 4 °C.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



EQUIPMENT AND MATERIALS REQUIRED BUT NOT SUPPLIED

- 1 mL micropipette.
- Sterile standard microtubes.
- MilliQ water or any other recommended buffer.
- Ethanol (EtOH) 96%.
- Drug of interest.

CONSIDERATIONS BEFORE STARTING

- The following protocol is optimized for the preparation of 1 mL of **DIVERSA**-**DRUG NANOPARTICLES** (starting from one **DIV010** vial for reconstitution).
- The drug loading should be optimized regarding the volume used to reconstitute the ethanolic phase of the DIV010 vial. For specific recommendations, contact <u>DIVERSA</u>.
- **DIVERSA** cannot guarantee the optimal characteristics of the final formulation if modifications in the protocol are introduced.
- It is recommended to use **DIVERSA-DRUG NANOPARTICLES** within 24-48 h, considering the stability of the drug.
- DIVERSA-DRUG NANOPARTICLES is stable for 6 h in cell culture media at 37 °C: DMEM and RPMI (with/without FBS).
- Do NOT use any buffer solution containing Triton X-100, SDS or Tween-20 for the preparation or manipulation of **DIVERSA-DRUG NANOPARTICLES**.
- Do NOT freeze **DIVERSA-DRUG NANOPARTICLES**.
- Do NOT heat up **DIVERSA-DRUG NANOPARTICLES** formulation at temperatures higher than 90 °C for more than 2 h.
- Do NOT centrifuge or vortex **DIVERSA-DRUG NANOPARTICLES**.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.



www.diversatechnologies.com info@diversatechnologies.com

DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES PROTOCOL FOR HYDROPHOBIC DRUGS

1. Reconstitute the DIV010 vial with 50 μ L of EtOH. Pipette up and down gently for mixing the lipids trying to recover all of them from the vial wall and keep the suspension in the vial.

Note: This volume depends on the solubility of your drug. However, the minimum volume to reconstitute the lipids that we recommend is $20 \,\mu$ L.

- 2. Add the drug dissolved in one of the solvents suggested in <u>Table 1</u> (Recommendations of Use and Technical Notes) to DIV010 vial, considering the maximum volume for each solvent.
- 3. Adjust the volume of the mixture with EtOH up to a final volume of 100μ L.
- **4.** Add 900 μ L of ultrapure water into the **DIVTECH** vial or, alternatively, a buffer solution suggested in <u>Table 2</u> (Recommendations of Use and Technical Notes).
- 5. Transfer the whole volume from the DIV010 vial containing the drug to the DIVTECH vial using a micropipette and the 1 mL micropipette tip provided.

IMPORTANT: Before adding the lipids and drug mixture from **DIV010** vial to the **DIVTECH** vial, set the micropipette at the maximum volume to have dead air volume in the tip for mixing in a faster and vigorous way. Then, place the 1 mL micropipette tip into the buffer solution of **DIVTECH** vial, and pipette up and down for 30 seconds, avoiding any spillage.

The **DIVERSA-DRUG NANOPARTICLES** now ready-to-use for *in vitro* and *in vivo* experiments. Alternatively, keep it at 4 °C and use it in the following 24-48 h.

Note: for *in vitro* experiments, the adherent cells must be between 70-80% of confluency on the day of the experiment. However, optimizations should be required depending on the cell type.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



www.diversatechnologies.com info@diversatechnologies.com



Figure 1. DIVERSA SMALL MOLECULE DELIVERY NANOPARTICLES protocol for hydrophobic drugs.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: <u>info@diversatechnologies.com</u> | <u>www.diversatechnologies.com</u>



PROTOCOL FOR HYDROPHILIC DRUGS

- 1. Reconstitute the DIV010 vial with 100μ L of EtOH. Pipette up and down gently for mixing the lipids trying to recover all of them from the vial wall and keep the suspension in the vial.
- **2.** Dissolved the drug in 900 μ L of ultrapure water into the **DIVTECH** vial or, alternatively, a buffer solution suggested in <u>Table 2</u> (Recommendations of Use and Technical Notes).
- **3.** Transfer the whole volume from the **DIV010** vial the **DIVTECH** vial containing the drug using a micropipette and the 1 mL micropipette tip provided.

IMPORTANT: Before adding the lipids from **DIV010** vial to the **DIVTECH** vial containing the drug, set the micropipette at the maximum volume to have dead air volume in the tip for mixing in a faster and vigorous way. Then, place the 1 mL micropipette tip into the buffer solution of **DIVTECH** vial, and pipette up and down for 30 seconds, avoiding any spillage.

The **DIVERSA-DRUG NANOPARTICLES** now ready-to-use for *in vitro* and *in vivo* experiments. Alternatively, keep it at 4 °C and use it in the following 24-48 h.

Note: for *in vitro* experiments, the adherent cells must be between 70-80% of confluency on the day of the experiment. However, optimizations should be required depending on the cell type.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com





Figure 2. DIVERSA SMALL MOLECULE DELIVERY REAGENT protocol for hydrophilic drugs.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



PROTOCOL OPTIMIZATION PROTOCOL FOR DRUG LOADING OPTIMIZATION

If you do not know the optimal drug loading of your molecule, it is highly recommended to test different drug loadings to get the best **DIVERSA NANOPARTICLES** performance.

1. Reconstitute the DIV010 vial with 50 μL of EtOH for <u>hydrophobic drugs</u> or 100 μL of EtOH for <u>hydrophilic drugs</u>. Pipette up and down gently for mixing the lipids trying to recover all of them from the vial wall and keep the suspension in the vial.

Note: In the case of <u>hydrophobic drugs</u>, the minimum volume to reconstitute the lipids that we recommend is 20 $\mu L.$

2. Prepare smaller aliquots from 10 μL or higher as suggested in <u>Table 4</u> (Recommendations of Use and Technical Notes) depending on the drug loadings you would like to test.

Example: The total mass of lipids in the **DIV010** vial is 5.51 mg. In the case of <u>hydrophobic</u> <u>drugs</u>, if you want to test different drug loadings such as 1%, 5%, 10%, 15% and 20% (w/w), you could prepare 5 aliquots of 10 μ L, which contain 1.1 mg of total lipid mass. For example, the drug loading of 10% (w/w) will be 110.2 μ g of drug, and so on.

Note: Aliquots can be directly used for drug loading or kept at -20 °C up to 60 days.

- 3. From now on, follow the protocol depending on the nature of your drug:
 - For <u>hydrophobic drugs</u>: add the drug dissolved in one of the solvents suggested in <u>Table 1</u> (Recommendations of Use and Technical Notes) to DIV010 vial, considering the maximum volume for each solvent. Then, adjust the volume of the mixture with EtOH up to a final volume of 100 μ L. Finally, add 900 μ L of ultrapure water into the DIVTECH vial or, alternatively, a buffer solution suggested in <u>Table 2</u> (Recommendations of Use and Technical Notes).
 - For <u>hydrophilic drugs</u>: dissolved the drug in 900 μL of ultrapure water into the **DIVTECH** vial or, alternatively, a buffer solution suggested in <u>Table 2</u> (Recommendations of Use and Technical Notes).

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.



4. Transfer the whole volume from the **DIV010** vial to the **DIVTECH** vial using a micropipette and the 1 mL micropipette tip provided.

IMPORTANT: Before adding the lipids from **DIV010** vial to the **DIVTECH** vial, set the micropipette at the maximum volume to have dead air volume in the tip for mixing in a faster and vigorous way. Then, place the 1 mL micropipette tip into the buffer solution of **DIVTECH** vial, and pipette up and down for 30 seconds, avoiding any spillage.

The **DIVERSA-DRUG NANOPARTICLES** now ready-to-use for *in vitro* and *in vivo* experiments. Alternatively, keep it at 4 °C and use it in the following 24-48 h.

Note: for *in vitro* experiments, the adherent cells must be between 70-80% of confluency on the day of the experiment. However, optimizations should be required depending on the cell type.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



EXAMPLE OF ALAMAR BLUE ASSAY CYTOTOXICITY PROTOCOL

- 1. Seed the recommended number of the cells in a black 96-well plate in 100 μ L of complete medium the day before of the cytotoxicity assay.
- 2. The following day, dilute (if needed) the concentrations of DIVERSA-DRUG NANOPARTICLES to be tested (6-8 concentrations are recommended for a dose-response curve) to a final volume of $25 \,\mu$ L.
- **3.** Add this volume to the cells in the 100 μ L of complete medium.

Note₁: 4-6 replicates per concentration are recommended. Note₂: The final concentration of the DIVERSA-DRUG NANOPARTICLES in the well represents a 1/5 dilution.

Note₃: if you know the IC50 of your small molecule, you could select 3 higher doses and 3 lower doses. For instance, if the IC50 of the drug is 9 μ M, the lower doses could be 0,3 μ M, 1 μ M and 3 μ M and the higher doses could be 27 μ M, 81 μ M and 143 μ M.

- 4. Add the proper controls:
 - As a negative control (0% cell death): add the same concentration of **DIVERSA NANOPARTICLES** without the drug at the higher dose tested in a final volume of $25 \,\mu$ L.

Note: you could also use untreated cells, adding the same volume of the media in which the DIVERSA-DRUG NANOPARTICLES is resuspended, e.g.: 25 μ l/well of ultrapure water or PBS 1X buffer.

- As a positive control (100% cell death): add Triton 1% (v/v) dissolved in PBS.
- For the blank (background data): medium and nanoparticles will be placed in one of the empty columns.
- 5. The incubation times may vary depending on the experiment, from 2 to 72 h.
- 6. Dilute the Alamar Blue reagent at 10% (v/v) in free red-phenol cell culture medium supplemented with 10% (v/v) of Fetal Bovine Serum.

Note: We recommend use free red-phenol cell culture medium to avoid signal interference.

7. After incubation time: remove the cell culture medium with the DIVERSA-DRUG NANOPARTICLES. Carefully, wash the cells with PBS 1X buffer and remove it.

Note₁: we recommend wash the cells with PBS 1X buffer containing calcium and magnesium ions to avoid maximum detachment of living cells.

8. Add 100 μl of the Alamar Blue reagent at 10% (v/v) per well (Product Ref.: DAL1025, Invitrogen) and incubate for 3-4 h at 37 °C and protect it from light.

Note₂: We recommend use a multichannel pipette to minimize the variability of the experiment.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: <u>info@diversatechnologies.com</u> | <u>www.diversatechnologies.com</u>



- **9.** After incubation time: measure the fluorescence signal using a microplate reader and the following parameters: wavelength of excitation at 570 nm, wavelength of emission at 585 nm.
- **10.** For analysis, background values are subtracted. The cytotoxicity is determined as the ratio between the measured fluorescence values of treated and untreated cells.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



RECOMMENDATIONS OF USE & TECHNICAL NOTES

Table 1. This table shows the maximum volumes of solvents in which the drugs can be dissolved and incorporated to the DIV010 vial.

SOLVENT*	VOLUME
EtOH	Up to 80 µL
DMSO	≤ 25 µL
MeOH	≤ 25 µL
ACN	≤ 25 µL
Acetone	≤ 25 µL
Chloroform	≤ 10 µL

*Solvent of preference: EtOH.

Note: kept the drug concentration in the preparation (1 mL) lower than 0.75 mg/mL, irrespective of the solvent.

Table 2. Suggested buffer for **DIVTECH** vial.

BUFFER SOLUTION	CONCENTRATION
Ultrapure water	N/A
PBS	2-50 mM
NaCl	150 mM
HEPES	10-25 mM
DPBS	1X

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: info@diversatechnologies.com | www.diversatechnologies.com



Cell culture vessel	Volume of DIVTECH	Volume of medium	Final volume/well
100 cm	200 µL	4,8 mL	5 mL
6-well	40 µL	960 mL	1 mL
12-well	20 µL	996 µL	500 µL
24-well	10 µL	240 µL	250 μL
96-well	4 µL	96 µL	100 µL

Table 3. Recommended volumes for cell culture.

Table 4. Recommended volumes to reconstitute the ethanolic phase of the DIV010 vial and the aqueous phase of the DIVTECH vial when <u>hydrophobic drug</u> loading optimization is required.

DIV010 vial reconstitution volume	Hydrophobic drug solvent volume	DIVTECH vial	Total volume of formulation	Micropipette for formulation
5 µL	5 µL	90 µL	100 µL	2-20 µL
10 µL	10 µL	180 µL	200 µL	00.000 vi
25 µL	25 µL	450 µL	500 μL	20-200 µL

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: <u>info@diversatechnologies.com</u> | <u>www.diversatechnologies.com</u>



FREQUENTLY ASKED QUESTIONS

QUESTION	ANSWER
How do I concentrate the formulation?	If necessary, the 1 mL of DIVERSA-DRUG NANOPARTICLES can be concentrated by using a SpeedVac or Rotavap in mild conditions (avoid overpassing 35 °C or drying out the samples). Samples can be concentrated up to 4-fold its original volume (i.e., to a final volume 250 μ L).
Can I filter the formulation?	Yes, if necessary, DIVERSA-DRUG NANOPARTICLES can be filtered using 0.22 μm filters of PES membrane.
What should I do if my drug is not soluble in EtOH?	You can use any solvent listed in <u>Table 1</u> . You can also sonicate DIV010F1 vial containing the drug prior addition to the DIVTECH vial.
Can I use buffers other than milliQ water?	Yes, please check <u>Table 2</u> for other recommended buffers.
How can I measure the size of the final formulation?	Diameter size can be measured by Dynamic Light Scattering (DLS) analysis adding to the cuvette 10 µl of DIVERSA-DRUG NANOPARTICLES with 990 µl of MilliQ water.
Can I use DIVTECH for in vivo studies?	Yes, DIVERSA-DRUG NANOPARTICLES can be used <i>in vivo</i> . For specific recommendations and a customized and optimized prototype, contact <u>DIVERSA</u> .

ONLINE RESOURCES

Visit our website www.diversatechnologies.com for further information.

Shipping temperature may differ from storage temperature. This does not alter the performance of the product.

DIVERSA TECHNOLOGIES S.L. | Edificio Emprendia, Campus Sur, 15782, Santiago de Compostela, Spain.

Technical support: email: <u>info@diversatechnologies.com</u> | <u>www.diversatechnologies.com</u>